Concert Pharmaceuticals Inc (CNCE) Holdings Lifted by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. raised its position in Concert Pharmaceuticals Inc (NASDAQ:CNCE) by 8.6% in the second quarter, HoldingsChannel reports. The institutional investor owned 95,187 shares of the biotechnology company’s stock after purchasing an additional 7,500 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Concert Pharmaceuticals were worth $1,602,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Acadian Asset Management LLC increased its holdings in Concert Pharmaceuticals by 11.3% in the second quarter. Acadian Asset Management LLC now owns 941,282 shares of the biotechnology company’s stock valued at $15,841,000 after buying an additional 95,863 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Concert Pharmaceuticals by 122.1% in the first quarter. Dimensional Fund Advisors LP now owns 737,646 shares of the biotechnology company’s stock valued at $16,892,000 after buying an additional 405,592 shares in the last quarter. Northern Trust Corp increased its holdings in Concert Pharmaceuticals by 45.6% in the first quarter. Northern Trust Corp now owns 636,097 shares of the biotechnology company’s stock valued at $14,567,000 after buying an additional 199,090 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Concert Pharmaceuticals by 25.1% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 413,122 shares of the biotechnology company’s stock valued at $6,953,000 after buying an additional 82,922 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Concert Pharmaceuticals by 8.4% in the second quarter. Bank of New York Mellon Corp now owns 170,848 shares of the biotechnology company’s stock valued at $2,876,000 after buying an additional 13,204 shares in the last quarter. 73.25% of the stock is owned by institutional investors.

A number of research firms have weighed in on CNCE. Zacks Investment Research cut shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 3rd. BidaskClub raised shares of Concert Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, September 20th. Janney Montgomery Scott began coverage on shares of Concert Pharmaceuticals in a report on Thursday, September 13th. They issued a “neutral” rating for the company. ValuEngine cut shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 23rd. Finally, HC Wainwright reiterated a “buy” rating on shares of Concert Pharmaceuticals in a research report on Friday, August 3rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. Concert Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $26.80.

Shares of NASDAQ CNCE opened at $14.39 on Friday. Concert Pharmaceuticals Inc has a 52-week low of $12.33 and a 52-week high of $30.71. The stock has a market capitalization of $347.48 million, a PE ratio of 3.48 and a beta of 1.01.

Concert Pharmaceuticals (NASDAQ:CNCE) last announced its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.05. Concert Pharmaceuticals had a net margin of 67.52% and a negative return on equity of 19.73%. Sell-side analysts forecast that Concert Pharmaceuticals Inc will post -2.06 EPS for the current year.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.

Further Reading: Fundamental Analysis and Choosing Stocks

Want to see what other hedge funds are holding CNCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Concert Pharmaceuticals Inc (NASDAQ:CNCE).

Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply